Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1039 participants.

Also called NCT01093807

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,039 participants (enrolled count) (from the registry)
Sponsor
RECORDATI GROUP (from the registry)
Registry
  • NCT NCT01093807
Other papers using this trial's data
  • Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database Journal of hypertension, 2016-01 DOI, PubMed 26630216

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01093807. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension
Acronym
FELT
Condition
Essential Hypertension
Intervention (Drug)
Placebo
Intervention (Drug)
Lercanidipine
Intervention (Drug)
Lercanidipine
Intervention (Drug)
Enalapril
Intervention (Drug)
Enalapril
Intervention (Drug)
Lercanidipine + Enalapril
Intervention (Drug)
Lercanidipine + Enalapril
Intervention (Drug)
Lercanidipine + Enalapril
Intervention (Drug)
Lercanidipine + Enalapril
Lead sponsor
RECORDATI GROUP (class: industry)

Record details

Record id
cardio:ct-nct01093807
Content hash
a395a940c5a4f41b03aae39b6fcdf5f29f414032261ba8339b07813f913c2378